Targeted Field Privately held medical device company in Portland focused on cardiovascular therapy with VisOne SDS implant, presenting a clear opportunity to engage hospital systems, cardiology groups, and research institutions evaluating advanced heart failure interventions.

Growth Potential Small to mid-sized organization with 11-50 employees and $22M in funding, suggesting openness to partnerships, clinical collaborations, and early-adopter programs for reimbursement-ready data generation and EU/US market expansion.

Clinical Readiness Active in heart failure device development since at least 2017 with dedicated medical affairs leadership and clinical collaboration history, indicating readiness for multi-site trials, investigator-initiated studies, and clinical adoption initiatives.

Strategic Partnerships Past collaborations with Clinical Accelerator and a track record of academic and industry engagement imply alignment for contract research, training programs, and co-development opportunities with service providers and CROs.

Market Positioning Competing in a crowded but high-value space alongside CardioFocus and others, with a notable EuroPCR 2025 recognition; indicates a differentiator through innovative SDS therapy and potential for risk-sharing reimbursement conversations.